<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Huang J</submitter><funding>Canada Research Chairs Program of the Natural Sciences and Engineering Research Council</funding><funding>New Frontiers in Research Fund</funding><funding>Natural Sciences and Engineering Research Council Canada Graduate Scholarship Doctoral Program</funding><funding>Canadian Institutes of Health Research</funding><pagination>29</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12408339</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2(1)</volume><pubmed_abstract>We report a synthetic tetrahedral DNA nanocarrier (TDN) for treating bone defects and methicillin-resistant &lt;i>Staphylococcus aureus&lt;/i> (MRSA) infection using in vitro studies. We successfully synthesized TDNs and demonstrated their excellent cytocompatibility with blood cells and immune cells. Zoledronic acid-loaded TDN displayed increased efficacy compared to free drugs in regulating bone remodeling, while vancomycin-loaded TDN showed an increased antibacterial effect against MRSA. In the future, this nano-drug delivery platform, with its multifunctional properties, can be potentially used to treat bone fractures and surgery-related MRSA infection.</pubmed_abstract><journal>NPJ biomedical innovations</journal><pubmed_title>Self-assembled DNA nanocarrier-enabled drug delivery for bone remodeling and antimicrobial applications.</pubmed_title><pmcid>PMC12408339</pmcid><funding_grant_id>NFRFE-2019-00743</funding_grant_id><funding_grant_id>185629</funding_grant_id><funding_grant_id>CRC-2018-00028</funding_grant_id><pubmed_authors>Huang J</pubmed_authors><pubmed_authors>Zahid AA</pubmed_authors><pubmed_authors>Luo W</pubmed_authors><pubmed_authors>Paul A</pubmed_authors><pubmed_authors>Chakraborty A</pubmed_authors><pubmed_authors>Shamiya Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Self-assembled DNA nanocarrier-enabled drug delivery for bone remodeling and antimicrobial applications.</name><description>We report a synthetic tetrahedral DNA nanocarrier (TDN) for treating bone defects and methicillin-resistant &lt;i>Staphylococcus aureus&lt;/i> (MRSA) infection using in vitro studies. We successfully synthesized TDNs and demonstrated their excellent cytocompatibility with blood cells and immune cells. Zoledronic acid-loaded TDN displayed increased efficacy compared to free drugs in regulating bone remodeling, while vancomycin-loaded TDN showed an increased antibacterial effect against MRSA. In the future, this nano-drug delivery platform, with its multifunctional properties, can be potentially used to treat bone fractures and surgery-related MRSA infection.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-01T13:48:57.118Z</modification><creation>2026-04-08T13:11:06.5Z</creation></dates><accession>S-EPMC12408339</accession><cross_references><pubmed>40917680</pubmed><doi>10.1038/s44385-025-00020-2</doi></cross_references></HashMap>